# Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide

> The FDA approved Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate), sponsored by GILEAD SCIENCES, INC. (GILD), on February 7, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) |
| Codes |  |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | [HIV-1-Infection](https://sec-api.dev/indications/hiv-1-infection) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### February 7, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210251 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20180207, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22

### February 5, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210251 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210205, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22

### February 24, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210251 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210224, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22

### October 7, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210251 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20211007, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22

### October 14, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210251 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20221014, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22

### February 23, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210251 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20240223, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22

### April 24, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210251 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20240424, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22

### July 30, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210251 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20250730, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22

### March 16, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2/3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06613685 (Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-16 (ACTUAL); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06613685

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: HIV-1-Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06544733 (Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06544733

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: HIV-1-Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06544733 (Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06544733

## Same indication

- [Isl/len](https://sec-api.dev/pdufa/isl-len) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide

```bibtex
@misc{secapidev_pdufa_bictegravir_emtricitabine_tenofovir_alafenamide_20261116,
  title        = {Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bictegravir_emtricitabine_tenofovir_alafenamide_20261116","title":"Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
